hs-CRP: The Low-Grade Inflammation Signal Tied to Heart Risk

What hs-CRP actually is, and why it matters

High-sensitivity C-reactive protein (hs-CRP) is a protein your liver produces in response to immune activation. When tissues are stressed or damaged, immune messengers — chiefly interleukin-6 — signal the liver to release CRP into the bloodstream. The high-sensitivity assay detects very small concentrations, making it useful for identifying the subtle, chronic elevations relevant to cardiovascular and metabolic risk, not just the large spikes seen in acute infection.

What hs-CRP reflects about systemic inflammation

CRP's half-life is short and constant — approximately 19 hours. Because clearance is fixed, the circulating level is driven entirely by production rate, which in turn reflects upstream inflammatory signaling intensity. That makes hs-CRP a sensitive read on how actively the immune system is firing, not on kidney function or fluid shifts.

hs-CRP reflects inflammatory signaling intensity but does not identify the source — it rises with infections, autoimmune flares, visceral fat, sleep apnea, and post-exercise repair indistinguishably. A single elevated result requires context and repeat testing. When values exceed 10 mg/L, an acute process is the more likely explanation; retest after recovery before using the result for cardiovascular risk interpretation.

The high-sensitivity assay is calibrated for the 0.1–10 mg/L range relevant to vascular biology. Standard CRP is geared toward much higher levels. The two are not interchangeable, and comparing results across assay types can mislead.

In the JUPITER trial, people with normal LDL but elevated hs-CRP who took statins had fewer cardiovascular events, supporting the role of inflammatory tone in prevention strategies. Mendelian randomization studies suggest CRP itself may be more signal than cause — upstream immune pathways likely do the damage — but the signal still carries meaningful prognostic weight.

Reading your hs-CRP number against the reference range

The American Heart Association describes three cardiovascular risk tiers: below 1 mg/L (lower risk), 1–3 mg/L (average risk), and above 3 mg/L (higher risk). Values above 10 mg/L indicate an acute process rather than chronic cardiovascular risk and should be retested after recovery. These tiers are population-level guides, not diagnoses. Women, older adults, and people on estrogen therapy or during pregnancy often run higher values due to hepatic signaling effects. Assay calibration can also vary slightly between laboratories.

When levels run high

An elevated hs-CRP is common and non-specific. Recent illness, injury, dental work, a vaccine, or an intense workout can each raise hs-CRP for days. Chronic drivers include visceral adiposity, periodontal disease, sleep apnea, autoimmune conditions, chronic kidney disease, smoking, and estrogen-containing medications. If hs-CRP is modestly elevated and persists on repeat testing, clinicians consider related markers and risk factors together. For cardiovascular prevention, a persistently elevated hs-CRP is recognized as a risk-enhancing factor when 10-year ASCVD risk is borderline or intermediate — it does not indicate disease, but suggests inflammatory tone may warrant closer attention in the prevention plan.

When levels run low

A very low hs-CRP is common in healthy, well-recovered individuals; many active adults sit below 1 mg/L when sleep, nutrition, and metabolic health are well aligned. Rarely, a blunted CRP response can occur in severe liver dysfunction or profound immune suppression, but this would fit a broader clinical picture. A consistently low, stable value in an otherwise well person generally reflects lower inflammatory burden.

Why hs-CRP spikes: acute illness, chronic load, and more

Several distinct categories of influence shape where hs-CRP sits on any given draw.

Acute transient triggers — illness, injury, vaccination, dental procedures, and intense exercise — can elevate hs-CRP for 24–72 hours or longer. These spikes are expected and do not reflect chronic inflammatory burden. Draw timing matters: test when you are well, not during a cold, within 48 hours of intense exercise, or shortly after a vaccine. For cardiovascular risk assessment, two draws at least 2 weeks apart are the standard to account for these transient elevations.

Visceral adiposity is one of the most consistent chronic drivers. Adipose tissue — particularly around the abdomen — emits inflammatory cytokines that sustain elevated hs-CRP over time. Reductions in fat mass, by whatever means, tend to lower hs-CRP accordingly.

Sleep and circadian disruption raise sympathetic tone and inflammatory mediators. Short or irregular sleep schedules are associated with higher hs-CRP; consistent sleep patterns tend to reduce background immune noise.

Exercise presents a paradox. Acute intense sessions can spike hs-CRP briefly as muscle repair proceeds. Consistent training over time shifts the baseline downward by improving insulin sensitivity, reducing visceral fat, and increasing anti-inflammatory myokines from muscle.

Metabolic factors — insulin resistance, elevated fasting glucose, and poor glycemic control — intersect with inflammatory tone. Addressing metabolic dysfunction often lowers hs-CRP alongside glycemic markers.

Medications and therapies have direct effects. Statins lower hs-CRP beyond their LDL-reducing effect. Estrogen therapies raise it via hepatic signaling. Glucocorticoids and cytokine-targeting biologics tend to reduce it. These effects are independent of lifestyle and should be factored into interpretation.

Nutritional factors also play a role. Low vitamin D status, low magnesium adequacy, and low marine omega-3 intake each correlate with higher inflammatory markers in observational data, with modest reductions seen in some intervention trials. Curcumin has evidence for lowering CRP in specific contexts, though product quality and dosing are variable. Ultra-processed dietary patterns, excess added sugar, and frequent alcohol can push inflammatory signaling upward.

Other chronic conditions — periodontal disease, sleep apnea, autoimmune flares, and chronic kidney disease — sustain elevated hs-CRP independently of lifestyle factors and require clinical management.

Markers that read hs-CRP in proper context

• ApoB — ApoB counts atherogenic particles directly. Elevated ApoB alongside elevated hs-CRP maps lipid delivery burden in an inflamed vascular environment — a combination that carries more risk than either marker alone.
• Ferritin — ferritin is also an acute-phase reactant. Co-elevation with hs-CRP may reflect active inflammation or iron overload intersecting with liver stress. The pair together helps clarify whether a high ferritin is driven by inflammation or iron loading.
• ESR — ESR reflects plasma protein shifts over hours to days. Co-elevation of ESR and hs-CRP confirms systemic inflammation. They can diverge: hs-CRP rises faster in the early acute phase, while ESR may remain elevated after hs-CRP has normalized in chronic states.
• Albumin — albumin is a negative acute-phase reactant: it falls when hs-CRP rises with significant inflammation. A low albumin combined with elevated hs-CRP indicates a high inflammatory burden affecting hepatic synthesis.
• Fasting glucose — elevated fasting glucose alongside elevated hs-CRP links metabolic dysfunction to inflammatory tone. Addressing the metabolic root often lowers both markers in parallel.

When to retest hs-CRP for a real trend

hs-CRP's half-life of approximately 19 hours means production rate — not clearance — drives the level, and values can shift within days of a meaningful change in inflammatory load. This responsiveness is useful for monitoring, but it also means a single draw is easily distorted by transient events.

For cardiovascular risk assessment, the AHA recommends two draws at least 2 weeks apart to account for transient elevations from illness or exercise. Both draws should be taken when you are well — not during acute illness and not within 48 hours of intense exercise.

For monitoring chronic inflammation trends, retesting every 4–8 weeks is a reasonable interval after a meaningful lifestyle or clinical change, given that the underlying drivers (visceral fat, sleep, metabolic health) shift on a weeks-to-months timescale.

Use the same laboratory and the same assay type across draws. High-sensitivity (hs-CRP) and standard CRP assays are not interchangeable. If a result exceeds 10 mg/L, it likely reflects an acute process; retest after full recovery before using that value for risk interpretation.

When an elevated hs-CRP deserves a clinician's read

A single elevated hs-CRP rarely requires immediate action on its own — context and confirmation matter first. Repeat the test when you are well and at least 2 weeks from any acute illness, vaccine, or intense training block. If the elevation persists, that is the point at which a clinician's interpretation adds the most value.

Situations that warrant a clinical conversation include: hs-CRP consistently above 3 mg/L without an obvious transient explanation; values above 10 mg/L that persist after recovery from an acute illness; or any elevation that sits alongside borderline cardiovascular risk, unexplained metabolic changes, or symptoms that have not been explained by other testing. In these settings, hs-CRP can serve as a risk-enhancing factor that shifts prevention decisions — whether around lipid management, metabolic intervention, or further diagnostic workup.

Measuring hs-CRP is quick and inexpensive, and its value grows when trended over time alongside related markers. Paired with ApoB, fasting glucose, ferritin, and albumin, it helps map lipid burden, metabolic strain, and inflammatory tone together — moving beyond any single number toward a coherent picture of cardiovascular and metabolic health.

Superpower's approach to biomarker testing is built around exactly this kind of pattern recognition — tracking hs-CRP alongside the markers that give it meaning, interpreted by qualified clinicians, and trended over time so that changes in your internal environment become visible before they become symptomatic. Learn more at superpower.com or read about the approach.